Evidence map›Paper›PMID 32374087›Full record

ArticleCancer medicine2020

Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort.

Jasmine Lim, Akara Amantakul, Nisha Shariff, Bannakij Lojanapiwat, Adlinda Alip, Teng Aik Ong, Shankaran Thevarajah, Firdaus Ahmayuddin, Adeline Mathew, Supon Sriplakich and 3 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Jasmine LimDepartment of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0002-7501-1834
Akara AmantakulDepartment of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Nisha ShariffDepartment of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Bannakij LojanapiwatDepartment of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Adlinda AlipDepartment of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Teng Aik OngDepartment of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Shankaran ThevarajahDepartment of Urology, Queen Elizabeth Hospital, Kota Kinabalu, Malaysia.
Firdaus AhmayuddinDepartment of Urology, Queen Elizabeth Hospital, Kota Kinabalu, Malaysia.
Adeline MathewDepartment of Radiotherapy and Oncology, Sabah Women and Children Hospital, Kota Kinabalu, Malaysia.
Supon SriplakichDepartment of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Jaraspong VuthiwongDepartment of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Flora Li Tze ChongDepartment of Radiotherapy and Oncology, Sabah Women and Children Hospital, Kota Kinabalu, Malaysia.
Marniza SaadDepartment of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
University of Malaya · MYChiang Mai University · THQueen Elizabeth Hospital · MYSabah Environmental Trust · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is of much interest to understand the efficacy of abiraterone acetate (AA) in routine clinical practice. We assessed the clinical outcome of AA in patients with metastatic castration-resistant prostate cancer (mCRPC) and determined clinical factors associated with AA treatment duration in real-world setting. This real-world cohort consisted of 93 patients with mCRPC treated with AA in Thailand (58.1%) and Malaysia (41.9%). Primary endpoints were overall survival (OS) and biochemical progression-free survival (bPFS). Secondary endpoints were predictors associated with AA treatment duration evaluated with Cox proportional hazards regression. Around 74% were chemotherapy-naïve. The median AA treatment duration was 10 months (IQR 5.6-17.1). Malaysians had a relatively lower median OS and bPFS (OS 17.8 months; 95% CI 6.4-29.1, bPFS 10.4 months; 95% CI 8.8-12.0) compared to Thais (OS 27.0 months; 95% CI 11.3-42.7, bPFS 14.0 months; 95% CI 5.8-22.2), although it did not achieve statistical significance (P > .05). Patients with longer AA treatment duration (>10 months) had lower risk of death and longer bPFS, compared to those with shorter AA treatment duration (≤10 months) (hazard ratio [HR] 0.10, 95% CI 0.05-0.22 and HR 0.13, 95% CI 0.06-0.25, respectively). Multivariable analysis showed that PSA at AA initiation, presence of PSA response and chemotherapy-naive were independently associated with AA duration (P < .05). Abiraterone acetate is well-tolerated in the Southeast Asian cohort with comparable survival benefits to other Asian populations in real-world setting. Lower PSA levels at AA initiation, presence of PSA response, and chemotherapy-naive were significant in determining AA treatment duration.

Indexed as

Duration of TherapyAbiraterone AcetateAgedAntineoplastic AgentsCohort StudiesHumansKallikreinsMalaysiaMaleMiddle AgedMultivariate AnalysisNeoplasm GradingProgression-Free SurvivalProportional Hazards ModelsProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantAbiraterone AcetateAntineoplastic AgentsKallikreinsKLK3 protein, humanProstate-Specific AntigenchemotherapyMalaysiaoverall survivalprogression-free survivalPSA responseThailand

Identifiers

PMID32374087
PMCPMC7333845
OpenAlexW3021247992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.